(Q34565853)

3 August 2017

title

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons (English)

1 reference

3 August 2017

1 reference

1 reference

6

M S Sulkowski

1 reference

3 August 2017

D Alvarez

1

1 reference

3 August 2017

D T Dieterich

2

1 reference

3 August 2017

N Brau

3

1 reference

3 August 2017

L Moorehead

4

1 reference

3 August 2017

L Ball

5

1 reference

3 August 2017

publication date

1 October 2006

1 reference

Journal of Viral Hepatitis

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

683-689

1 reference

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Care of patients with hepatitis C and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Nucleoside analogues and mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00749.X

10.1111/J.1365-2893.2006.00749.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference